MDRX

Update in Lawsuit for Investors who purchased shares of Veradigm Inc. (NASDAQ: MDRX) announced by the Shareholders Foundation

Retrieved on: 
Tuesday, March 26, 2024
MDRX, SAN, Complaint, Allscripts, Security (finance)

SAN DIEGO, March 26, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in Veradigm Inc., f.k.a.

Key Points: 
  • SAN DIEGO, March 26, 2024 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in Veradigm Inc., f.k.a.
  • Allscripts Healthcare Solutions, Inc.
    Investors, who purchased shares of Veradigm Inc. (NASDAQ: MDRX) prior to February 2021 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
  • On November 22, 2023, an investor in NASDAQ: MDRX shares filed a lawsuit against Veradigm Inc. over alleged violations of securities laws.
  • Those who purchased shares of Veradigm Inc. (NASDAQ: MDRX) prior to February 2021 and continue to hold any of those shares, have also certain options and should contact the Shareholders Foundation, Inc.

Veradigm to Participate in TD Cowen Annual Health Care Conference

Retrieved on: 
Wednesday, February 28, 2024
Technology, Biotechnology, Health, Pharmaceutical, Professional Services, Artificial Intelligence, Other Science, Practice Management, Software, Data Analytics, Health Technology, Health Insurance, Science, Data Management, Inc., MDRX, Conference

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, today announced that Dr. Yin Ho, Veradigm interim Chief Executive Officer, and Lee Westerfield, interim Chief Financial Officer, will present at the TD Cowen Annual Health Care Conference on Monday, March 4, 2024, at 9:50 AM Eastern Time.

Key Points: 
  • Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, today announced that Dr. Yin Ho, Veradigm interim Chief Executive Officer, and Lee Westerfield, interim Chief Financial Officer, will present at the TD Cowen Annual Health Care Conference on Monday, March 4, 2024, at 9:50 AM Eastern Time.

Veradigm Receives Expected Delisting Notice from Nasdaq

Retrieved on: 
Wednesday, February 28, 2024
Data Management, Health, Technology, Health Technology, Other Technology, Mobile, Wireless, Software, Motion, Annual report, Calendar, Form, MDRX, Decision, Inc., Panel

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, announced today that, as expected, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the common stock of the Company from Nasdaq (the “Decision”).

Key Points: 
  • Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, announced today that, as expected, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the common stock of the Company from Nasdaq (the “Decision”).
  • The Decision indicates that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) and Nasdaq Listing Rule 5620(a).
  • The Company does not intend to request that the Nasdaq Listing and Hearing Review Council review the Decision.
  • The delisting also constitutes a “make-whole fundamental change” under the indenture pursuant to which the Company’s outstanding convertible notes were issued.

Veradigm Provides Update on its Financial Restatement Process

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Practice Management, Technology, Professional Services, Health, General Health, Pharmaceutical, Health Technology, Health Insurance, Data Analytics, Software, Acquisition, Sidley Austin, Annual report, Exercise, MDRX, Security (finance), Inc., Bank statement, Holding company

The Company plans to provide additional information regarding the anticipated delisting after it receives the expected notice from Nasdaq.

Key Points: 
  • The Company plans to provide additional information regarding the anticipated delisting after it receives the expected notice from Nasdaq.
  • The Company is working diligently to file its required financial statements, and ultimately to regain compliance with all of the Nasdaq Listing Rules and restore its listing as soon as practicable.
  • The Board believes that the current trading price of Company common stock does not reflect the Company’s intrinsic value.
  • J.P. Morgan Securities LLC is serving as financial advisor and Sidley Austin LLP is serving as legal counsel to the Company.

Veradigm to Acquire ScienceIO

Retrieved on: 
Tuesday, February 27, 2024
Technology, Biotechnology, Health, Pharmaceutical, Professional Services, Artificial Intelligence, Other Science, Practice Management, Software, Data Analytics, Health Technology, Health Insurance, Science, Data Management, Acquisition, AI, Growth, MDRX, Conference, Patient, Privacy, Hand, Inc., Partnership

Veradigm Inc. (NASDAQ: MDRX) (the “Company”), a leading provider of healthcare data and technology products and solutions, today announced that it has signed a definitive agreement to acquire ScienceIO.

Key Points: 
  • Veradigm Inc. (NASDAQ: MDRX) (the “Company”), a leading provider of healthcare data and technology products and solutions, today announced that it has signed a definitive agreement to acquire ScienceIO.
  • The transaction has been unanimously approved by the Veradigm Board of Directors and is expected to close as promptly as practicable following the satisfaction of customary closing conditions.
  • Founded in 2019, ScienceIO is a leading AI platform and foundation model provider for healthcare.
  • “Joining Veradigm aligns with ScienceIO’s mission to better serve patients and healthcare professionals with the help of responsible AI.

Veradigm to Highlight New EHR-Integrated Care Gap Alert Solution at ViVE 2024 Conference

Retrieved on: 
Thursday, February 22, 2024
Data Management, Biotechnology, Practice Management, Technology, Professional Services, Health, Pharmaceutical, Health Technology, Health Insurance, Data Analytics, Software, EHR, MDRX, Documentation, ViVe, Patient, Inc., Workflow, Health care

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will be highlighting the new Veradigm Payer Insights solution at the ViVE 2024 conference in Los Angeles, CA, Feb 25-28.

Key Points: 
  • Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that it will be highlighting the new Veradigm Payer Insights solution at the ViVE 2024 conference in Los Angeles, CA, Feb 25-28.
  • Gap closure is an important element in driving improved overall patient care and outcomes, but providers are not always aware of every gap that exists for their patients.
  • As part of the Veradigm Network, Veradigm Payer Insights is a dynamic new solution which payers can use to deliver care gap alerts to their providers, within the patient’s electronic health record (EHR) system.
  • "We are excited to be at ViVE 2024 sharing the power of Veradigm Payer Insights, another example of how the Veradigm Network is adding value for all healthcare stakeholders from payers to providers and beyond,” said Tom Langan, Veradigm President and Chief Commercial Officer.

Veradigm Reveals New Insights on the Prevalence of Cardiovascular Conditions in the U.S.

Retrieved on: 
Tuesday, February 20, 2024
Data Management, Health, Technology, Health Technology, Software, General Health, Cardiology, Real-World Evidence, Woman, Cardiovascular disease, EHR, CVD, MDRX, Data, Heart failure, Prevalence, Natural language processing, Hypertension, BMI, Death, Patient, Natural language, Body mass index, LVEF, Coronary artery disease, NLP, Dietary supplement

Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.

Key Points: 
  • Veradigm today released its inaugural Veradigm Insights Report: Cardiovascular Conditions in 2024, which examines de-identified real world data for 53 million unique cardiovascular patients.
  • Using structured and unstructured data from the comprehensive Veradigm Network EHR dataset, the report presents cardiovascular condition prevalence by state and three-digit zip code.
  • Veradigm also examines the prevalence of cardiovascular conditions such as dyslipidemia/hyperlipidemia and hypertension in relation to body mass index (BMI) categories.
  • Veradigm has a variety of additional data sources including clinically enriched Veradigm Network EHR Data across various therapeutic areas and the Veradigm Cardiovascular and Metabolic Registries.

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

Retrieved on: 
Tuesday, February 13, 2024
Health Technology, White House, Federal Government, Data Management, Other Education, Technology, Practice Management, Pharmaceutical, Education, Professional Services, Infectious Diseases, Public Policy, Government, Cardiology, Biotechnology, Software, Data Analytics, Health, Senior, MD, Physician, American College of Cardiology, Cardiovascular disease, ACS, Practice management, EHR, Stroke, MBA, SCM, MDRX, Risk, HHS, Heart failure, Vaccination, Unitary state, CMSS, American College, Council, Acute coronary syndrome, Patient, Practice Fusion, CDC, ACC, Inc., VAX, Medical specialty, Evidence-based practice, Workflow, Pharmaceutical industry

Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education.

Key Points: 
  • Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM VAX, an American College of Cardiology (ACC)-sponsored initiative aimed at improving cardiovascular health through increased influenza vaccination education.
  • Influenza vaccination is associated with a lower risk for adverse cardiovascular events, with an overall 34% lower risk of major adverse cardiovascular events and a 45% lower risk among individuals with recent acute coronary syndrome (ACS).1 As part of this quality improvement initiative, Veradigm is delivering ACC-sponsored vaccination education messaging to a subset of cardiology practices using the Practice Fusion EHR (a Veradigm Network solution).
  • The messages appear as banner advertisements in an in-frame window adjacent to the EHR workflow that is separate and distinguishable from the clinical and practice management workflow within the EHR.
  • “Veradigm is proud to be working with the ACC to apply our real-world data in combination with our messaging capabilities to improve rates of recommended vaccinations for adults with cardiovascular disease,” said Stuart Green, Senior Vice President and General Manager at Veradigm.

MDRX IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Veradigm Inc. f/k/a Allscripts Healthcare Solutions, Inc. Investors to Secure Counsel Before Important January 22 Deadline in Securities Class Action - MDRX

Retrieved on: 
Friday, January 19, 2024
Titan, Class, MDRX, Court, GAAP, Advertising, Plaintiff

WHAT TO DO NEXT: To join the Veradigm class action, go to https://rosenlegal.com/submit-form/?case_id=20675 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Veradigm class action, go to https://rosenlegal.com/submit-form/?case_id=20675 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Veradigm Inc.(MDRX) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Monday, January 22, 2024
NEXT, LLP, MDRX, Court, COST, Telephone, CLASS, Cryptocurrency

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ: MDRX) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Veradigm Inc. ("Veradigm" or the "Company") (NASDAQ: MDRX) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Veradigm investors who were adversely affected by alleged securities fraud between February 26, 2021 and December 7, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    MDRX investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.